key: cord-0818250-fysbhrfx
authors: Harris, Jeffrey E.
title: The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines
date: 2022-03-21
journal: Health Policy Technol
DOI: 10.1016/j.hlpt.2022.100619
sha: a458d318251d02df97ca0c214fa984e47eae5f9e
doc_id: 818250
cord_uid: fysbhrfx

The decades-long effort to produce a workable HIV vaccine has hardly been a waste of public and private resources. To the contrary, the scientific know-how acquired along the way has served as the critical foundation for the development of vaccines against the novel, pandemic SARS-CoV-2 virus. We retell the real-world story of HIV vaccine research – with all its false leads and missteps – in a way that sheds light on the current state of the art of antiviral vaccines. We find that HIV-related R&D had more than a general spillover effect. In fact, the repeated failures of phase 2 and 3 clinical trials of HIV vaccine candidates have served as a critical stimulus to the development of successful vaccine technologies today. We rebut the counterargument that HIV vaccine development has been no more than a blind alley, and that recently developed vaccines against COVID-19 are really descendants of successful vaccines against Ebola, MERS, and SARS. These successful vaccines likewise owe much to the vicissitudes of HIV vaccine development. We then discuss how the failures of HIV vaccine development have taught us how adapt SARS-CoV-2 vaccines to immune escape from emerging variants. Finally, we inquire whether recent advances in the development of vaccines against SARS-CoV-2 might in turn further the development of an HIV vaccine - what we describe as a reverse spillover effect.

Scientists and policymakers have been fretting for decades about our failure to develop an effective, workable vaccine against human immunodeficiency virus (HIV). The basic science is extraordinarily complex, many researchers have rightly noted [1] . Antiretroviral drugs were the path of least resistance, others have cogently observed [2] .

The principal conclusion of this review article is that the decades-long effort to produce a workable HIV vaccine has hardly been a failure. To the contrary, the scientific know-how acquired along the way has served as the critical foundation for the development of vaccines against the novel, pandemic SARS-CoV-2 virus. While it is already widely acknowledged that HIV-related research has had substantial spillover effects [3, 4] , our thesis is more pointed. We Our methodology is primarily historical. We retell the story of HIV vaccine research in a way that sheds light on the current state of the art of antiviral vaccines. The manifold scientific reasons why it is so difficult to engineer an HIV vaccine were simply unknown when the U.S.

Secretary of Health and Human Services announced in a famed April 1984 press conference that a preventive vaccine would be ready for testing within two years [5, 6] . As researchers encountered a succession of unanticipated obstacles, they tried out new models of vaccine delivery that ultimately failed to overcome HIV but turned out to have wide application to the control of COVID-19 and other infectious diseases.

On February 4, 2020, the U.S. National Institute of Allergy and Infectious Diseases announced that it was halting its clinical trial of yet another candidate vaccine against HIV [7] .

The trial, called Uhambo, tested a vaccine based on canarypox, a live bird virus that can infect human cells without causing disease. The canarypox virus had been genetically altered to induce infected human cells to manufacture several key proteins of the HIV virus [8] . These proteins, it was hoped, would then stimulate the vaccine recipient's immune system to protect against future infection by HIV.

The Uhambo trial had been conducted in 14 sites across South Africa, enrolling over 5,400 HIV-negative participants 18-35 years old. More than half-way through the study, researchers had unsealed the data to find that the intervention and control groups had about the same number of new cases of HIV. "While we are obviously disappointed in the results,"

commented Winnie Byanyima, Executive Director of UNAIDS, "important science has been learned that can be carried forward to future trials." [9] Byanyima's comment was precisely on target. Large-scale, complex scientific and technological research enterprises, including the task of developing and testing a vaccine against HIV, involve what economists call learning by doing [10] . It is not simply that the research team becomes more efficient at producing the candidate vaccine or carrying out a trial on human subjects. Researchers gain insights from their mistakes. The suspension of Uhambo was just the latest in a decades-long series of failures to find a vaccine against HIV and, in the process, to learn by trying, failing, rethinking, and trying again (Table 1) .

[ HLPT-S-21-00479_R1 24-Feb-2022 5 A great many of the candidate HIV vaccines that have been tested over the last three decades were originally developed by private firms and protected by patents. The private firms holding these patents have been competing for a very valuable prize. If a candidate vaccine turns out to be effective, its patent holder wins big. But when the candidate vaccine fails, all the competitors in the vaccine fieldnot just the patent holderlearn from the mishap. The patent holder can reap the rewards of success, but it cannot fully capture the gains from its mistakes.

We thus have a positive externality, specifically a knowledge spillover [19, 20] . An HIV vaccine trial ending in failure may still have an extraordinarily large social benefit even if its private benefit turns out to be vanishingly small, or even negative.

Before the HIV epidemic of the 1980s, vaccines were made primarily through two conventional methods. First, inactivated whole virus vaccines were produced by heat or chemical treatment of the infectious organism (Fig. 1) . The Salk polio vaccine was produced by treating the poliovirus with formaldehyde [21] , a component of embalming fluid. Second, live attenuated virus vaccines were produced by repeatedly passing the infectious organism through animals, cell lines, or unfavorable conditions in order to induce mutations that would render it harmless but still infectious (Fig. 2) . The original measles vaccine was made by passing the measles virus through cell cultures of human organs and chick embryos, as well as embryonated hen's eggs [22] . It wasn't clearly known why these two approaches worked, but they were enormously successful in combating not only polio and measles, but also rabies, mumps and rubella [23, 24] .

Still, when it came to the novel problem of combating a virus that lay dormant in an infected person's body for years before it emerged as deadly AIDS, these conventional technologies were considered too risky. The virus is chemically treated (left) so that it is unable to infect host cells (center) but can still stimulate an immune response when injected (right) into the recipient. Inactivated virus vaccines against SARS-CoV-2, including those manufactured by Sinovac [25] , Sinopharm [26] , and Bharat [27] , are produced by treating the virus with beta propiolactone (BPL). Because the inactivated virus cannot by itself infect cells and thus stimulate cellular immunity, inactivated virus vaccines need to be administered with a mixture of aluminum salts called an adjuvant [28, 29] . All figure credits: the author. 

The virus is repeatedly passed through unfavorable conditions in order to induce mutations that render it harmless but still infectious. Currently, hepatitis A vaccine is available in both inactivate virus and live attenuated virus forms [30] . As of February 15, 2022, two live attenuated virus vaccine candidates against SARS-CoV-2 were in phase 1 or 2 clinical trials, but none was currently marketed. See Table 2 below.

The inactivated virus vaccine model was frowned upon chiefly because there was a material risk that the virus would not be completely inactivated [31] . In fact, inactivated whole virus vaccine candidates that advanced to the point of evaluation in human subjects have been rare. One such vaccine candidate named REMUNE, developed by a biotech company cofounded by Jonas Salk in 1986, was ultimately abandoned in 2007, apparently because the chemical treatment required for inactivation also stripped the virus of a key molecule that stimulated immunity [32] . In a subsequent attempt to produce a workable whole virus vaccine, HIV was first genetically modified to knock out some of the genes responsible for its infectivity and then chemically inactivated. The vaccine candidate, named SAV001 developed by SumaGen Canada, a member of the Seoul-based Curo Group [33] , was evaluated in a phase 1 human clinical trial in 2013 [34] , but has not advanced further.

Serious safety concerns likewise surrounded the application of the live attenuated virus model to the development of an HIV vaccine [35] . At least early on, it wasn't known what mutation was responsible for rendering the virus harmless. If the virus had been attenuated as a result of an unknown mutation, there was a genuine possibility that it could revert to its more virulent form as a result of a back mutation, or perhaps a separate compensatory mutation [36] .

Added to this concern was the possibility that supposedly attenuated viruses might still cause disease in patients whose immune system had been weakened by HIV. Finally, there was the concern that the attenuated virus could recombine with a virulent, wild form of HIV.

Humans and other animals have evolved a dual, partly complementary and partly redundant system of defenses against noxious infectious agents [37] . Under humoral immunity, the defending animal produces antibodies that claw onto and neutralize molecules called antigens. Under cellular immunity, a specialized army of cells, including certain white blood HLPT-S-21-00479_R1 24-Feb-2022 7 cells called killer lymphocytes, work in concert to destroy the offender. The distinct roles of humoral and cellular immunity are especially important in the host's defenses against latent viruses such as varicella zoster virus (VZV). Both the humoral and cellular systems are involved in the initial response to chickenpox caused by a VZV infection. A shingles outbreak occurs when cellular immunity is later weakened [38] .

From the start of the HIV epidemic, there was growing evidence that the host's defenses against the virus were especially dependent on cellular immunity. As early as 1985, it was known that HIV stimulated the development of neutralizing antibodies in most infected people, who then became "HIV-positive," but that those antibodies alone were insufficient to confer protection against disease [39, 40] . When an individual was initially infected, it was found, the killer lymphocytesnot the antibodieswere responsible for tamping down the spread of the virus [41] [42] [43] [44] . In fact, progression of HIV infection to AIDS was associated with escape from killer lymphocyte control [45] . Studies of individuals called elite controllers, who were chronically infected but never seemed to progress to AIDS, even without treatment, confirmed they were shielded by their cellular immune system [46, 47] .

Viruses are microscopic organisms consisting of a nucleic acideither DNA or RNAsurrounded by a protein shell. Viruses are parasites. They cannot reproduce on their own. Instead, they infect host cells and then use the infected cell's machinery to produce more viruses.

While both SARS-CoV-2 and HIV are RNA viruses, they act very differently once they have infected a host cell. SARS-CoV-2, like other coronaviruses, uses the genetic instructions in its viral RNA to directly make copies of itself in the host cell cytoplasm. HIV, on the other hand, relies upon a more roundabout process to convert its viral RNA back to viral DNA, which then gets imported into the host cell nucleus and integrated into the host's own DNA, where it can remain latent for years [48] . This roundabout process is extremely prone to error and thus results in extraordinarily high rates of viral mutation.

We are by now accustomed to the fact that SARS-CoV-2 undergoes mutation, and that these mutations can result in the emergence of new viral variants [49] . We are likewise accustomed to the mutation-induced variations of influenza virus strains that require repeated seasonal flu vaccinations [50] . But the mutability of HIV turned out to be an order of magnitude In what later became known as the transmitted founder effect, a single virus was almost always found to be involved in the initial transmission of an HIV infection from one person to another [51] . But within months, the transmitted founder was replaced by mutated viruses that did not react to antibodies developed by the infected person and thus might escape humoral immune control [52] . By one estimate, the genetic diversity of HIV within a single infected patient exceeded the worldwide diversity of influenza virus during an entire season [53] .

In addition to the basic protein shell encasing the inner nucleic acid, many viruses have an extra envelope containing glycoproteins, which are proteins coated with sugary molecules called glycans. Among these enveloped viruses are Ebola, hepatitis C, the Epstein-Barr virus, the coronaviruses SARS and SARS-CoV-2, and HIV. In each virus, one of these glycoproteins functions as the key to unlock the hatch on the host cell membrane and thus allow the virus to invade the cell. But the viral envelope also contains a multitude of other glycans that help the virus evade the host's humoral immune system.

In the Ebola virus, for example, these other glycans serve as decoys, diverting the host's antibodies away from the key glycoprotein that causes disease [54] . The glycans in the envelope of SARS-CoV-2 shield about 40 percent of virus' protein surface, not enough to keep antibodies from clawing onto the spike glycoprotein that we have come to recognize as the virus' key to invading host cells [55] . The glycoprotein envelope of HIV, by contrast, was loaded with far more glycans than that of any other enveloped virus, making up about half of the weight of the entire virus particle [56] . HIV's glycan shield, researchers learned, seemed to be constantly evolving as the virus repeatedly mutated [57] .

Under the conventional, pre-HIV model of vaccination, the main strategy was to mimic the natural process of acquiring immune protection against the infectious agent. If contracting an infection naturally protected someone against getting it again, then the idea was to develop a vaccine that would make the blood of the vaccine recipient look like the convalescent serum of a recovered individual. HIV rendered this classical idea meaningless. The problem was that we HLPT-S-21-00479_R1 24-Feb-2022 9 didn't -and still don'thave a crystal-clear notion of what it means to naturally recover, and thus become naturally immune, to HIV [58] .

As HIV vaccine researchers began to work on the most effective combination of stimulants to both humoral and cellular immunity, a novel reevaluation of the basic paradigm was in order. Protection and natural recovery from infection may be different [37, 59] . That could mean, for example, that a sufficiently large stimulus to humoral immunity could confer protection even though the levels of antibodies seen in naturally infected individuals didn't appear to be sufficient. The same could apply to a sufficiently large stimulus to cellular immunity, much larger than among people naturally infected by HIV.

Through detailed analysis of HIV's molecular structure, researchers determined that the key molecule in the virus' envelope unlocking host cell membranes was a glycoprotein named gp120. This discovery led the way to a new model for potentially achieving immunity. Instead of using a whole virus to stimulate an immune responseas in the case of inactivated and live attenuated virusesthe approach would be to make a vaccine out of pure gp120. The goal was to artificially stimulate a sufficiently strong humoral antibody response to the pure glycoprotein molecule, even if that sort of response did not occur during natural infection ( vaccine recipient (right). The schematic omits an alternative process of producing the purified protein, known as recombinant technology, which involves identification of the viral genome that codes for the protein and then transferring the genetic code to a bacterial or mammalian cell that serves as a biological factory for producing the protein. The AIDSVAX B/B [11] and AIDSVAX B/E [12] trials of purified forms of gp120 failed to prevent HIV. Purified protein vaccines against SARS-CoV-2 in current use include those produced by Anhui Zhifei Longcom Biopharmaceutical [61] and Vektor State Research Center of Virology and Biotechnology [62, 63] . Other vaccine candidates derived from a purified form of the SARS-CoV-2 glycoprotein, developed by Novovax [64, 65] and by Sanofi and GSK [66] , have demonstrated efficacy in phase 3 clinical trials and are seeking regulatory approval.

Unfortunately, AIDSVAX B/B failed to curb HIV in a study of over 5,400 volunteers in the U.S and the Netherlands [11] , while AIDSVAX B/E performed no better in a study of over 2,500 injection drug users in Bangkok, Thailand [12] . The failures of these two candidate vaccines became the focus of a substantial research effort. Both vaccines did indeed stimulate a humoral response against gp120, but that alone did not offer protection against infection [67] .

Researchers acquired a growing appreciation of the phenomenon of immune escape [68] .

As we enter the third year of the COVID-19 pandemic, we have become keenly aware that mutations of SARS-CoV-2 can result in new variants that at least partially evade the immune responses induced by vaccines or naturally acquired infection [69] . By the early 1990s, researchers were already aware that, as a result of mutation, neutralizing antibodies against one isolated sample of HIV did not necessarily cross-neutralize other isolated samples [70] . They recognized that HIV could escape antibody neutralization by repeatedly mutating even within the same infected individual [71] . A key takeaway from the AIDSVAX failures was that immune escape was not simply the means by which the virus overcame an individual's weak natural antibody response, but it was going to be a critical impediment to effective vaccine development.

Reanalysis of the AIDSVAX data offered some evidence of a correlation between the protective effect and the cellular immune response to the vaccine, but the results were inconclusive [72] . Still, the findings brought home the possible key role of cellular immunity in the prevention of HIV infection. The idea was that an effective HIV vaccine would differ fundamentally from the smallpox vaccine, which generated enough antibodies to block viral entry entirelywhat we now call sterilizing immunity. Instead, transient infection would be permitted, but the virus would be cleared by the cellular immune systemwhat we now call infection-permissive immunity [73] . Having lived through the Omicron wave of SARS-CoV-2, HLPT-S-21-00479_R1 24-Feb-2022 11 we are now acutely aware that the cellular immune response to vaccines may help stave off the severe consequences of COVID-19 without blocking acute infection [74] . Back then, however, it was no more than a hypothesis.

Live Viral Vectors Become the New Model.

In the face of the failure of the AIDSVAX candidate vaccines to stimulate adequate humoral immunity against the key molecule gp120, and with growing evidence of the role played by cellular immunity in the defense against HIV infection, vaccine researchers turned to radically different models for conveying the immune stimulus [75] .

During the 1980s, a research team had managed to genetically engineer a live smallpox virus to produce a key protein from the surface of another virusthe hepatitis B virus.

Chimpanzees infected with this modified smallpox virus turned out to be immune against hepatitis B [76] . Of course, no one contemplated infecting a human being with smallpox in order to immunize him against hepatitis B. But the finding raised the possibility that a benign virus, once modified, could act as a live vector to produce immunogenic proteins from HIV (Fig. 4) . (left) is spliced together with DNA coding for the spike protein of the offending virus (center). The genetically modified, live infectious virus, when injected into the vaccine recipient (right), expresses the spike protein on its surface and thus stimulates immunity against the offending virus. The Merck STEP trial, which tested a combination of three Ad5-based viruses modified to express HIV genes gag, pol and nef, respectively, failed to prevent HIV infection [13] . Currently marketed viral vector vaccines against COVID-19 include those developed by Janssen (based on Ad26) [77, 78] and AstraZeneca and Oxford University (based on Ad5) [79] . Gem-COVID-Vac/Sputnik V, developed by Gamalaya Research Institute, is based upon a priming dose with an Ad26 vector and a booster dose with an Ad5 vector [29, 80] .

Efforts focused on a common-cold virus called adenovirus 5 (or Ad5) as a potential live vector [81] [82] [83] [84] . Evidence had accumulated, in particular, that a genetically engineered version of Ad5, once it naturally infected the cells of the vaccine recipient, could activate its newly acquired genes to boost anti-HIV cellular immunity [85] .

In the STEP vaccine trial, the pharmaceutical manufacturer Merck made a major, multimillion-dollar investment to test this concept [60] . Almost 3,000 participants were recruited Unfortunately, Merck's Ad5-based vaccine did not fully live up to expectations. While the vaccine stimulated cellular immunity [86] , it showed no reduction in HIV incidence compared to a placebo vaccine [13] . What's more, a participant's prior immunity to the Ad5 virus turned out to at least double the risk that he would come down with HIV during the trial [13] . As a result, the Phambili trial of the same vaccine in South Africa was cancelled [87] [88] [89] , while PAVE-100, another Ad5-based trial proposed for Africa and the Caribbean was put on hold [90] .

There were two competing explanations for the failure of Merck's STEP vaccine. One was that the whole concept of using a virus vector was flawed. The other was that adenovirus 5 simply wasn't the right vector. Perhaps vaccine recipients preferentially developed antibodies against the native proteins of Ad5, and not just against the artificial HIV proteins inserted into the vector's genetic code [85] . While Ad5 had been engineered to infect the host cells of the vaccine recipient without itself multiplying [91] , even this so-called replication-defective adenovirus 5 still stimulated a strong immune reaction in humans. In fact, a significant proportion of participants in the Merck STEP study already had antibodies to Ad5.

To help sort out why the Merck STEP vaccine failed, the RV144 trial, conducted by the 13 they were enrolled in the trial, or when they analyzed only those participants in the intervention group who received all vaccine doses [14] . Still, the problem was that an efficacy of about 31 percent simply wasn't enough to make the vaccine realistically useful for HIV prevention.

A leading explanation for the weak protection offered by RV144 was that the canarypoxbased primer and AIDSVAX-based booster, administered together during the first 6 months of the trial, were inadequate to sustain a strong immune response over 3.5 years of follow-up. Posthoc analysis of the trial data indicated that regimen had an initial efficacy of about 60% during the first year but waned rapidly during the next two years [14, 92, 93] .

To explore that possibility, a public-private collaborative team called the Pox-Protein adapted to HIV subtype C, which is more prevalent in South Africa [16] . We already know that Uhambo was called off in February 2020 [7, 9] .

Uhambo, however, was not the only variation of the vector-based prime-boost strategy designed to extend the partially successful results of RV144 [90] . An alternative strategy was to combine immune-stimulating antigens from a variety of subtypes of HIV within the same viral vector. The Imbokodo trial in women (HVTN 705), sponsored by Janssen in collaboration with a consortium of global partners, used an adenovirus 26 vector encoding proteins from a mosaic of different HIV subtypes in a series of four primer doses 6 months apart, along with purified gp140, another key protein on HIV's envelope, as booster doses 12 months apart [17] . In August 2021, Imbokodo was discontinued when the vaccinated and placebo groups showed no significant difference in HIV rates during 24 months of follow-up [94] . The Mosaico trial in men (HVTN 706), also sponsored by a Janssen-led consortium and still in progress, is relying up the same vector-based primer with a different gp120-based booster [18] .

The fabrication of vector-based vaccines entailed multiple laborious steps: extracting the critical sequences of RNA from key HIV genes, then converting these RNA sequences into DNA sequences, and then inserting these DNA sequences into the genome of a DNA-based vector virus (Fig. 4) . Would it be more efficient to copy the key HIV gene sequences into messenger RNA (or mRNA), the form of RNA that cells naturally use to crank out multiple copies of proteins? If not mRNA, then why not at least work with the corresponding sequences of DNA?

The use of freestanding nucleic acids, it was understood, might be vastly easier than inactivating or attenuating a whole virus, or inserting a gene into another vector virus. Those vaccine technologies had to be customized for each virus and, in some cases, each strain of each virus. When the 2009 H1N1 pandemic hit, vaccine developers took six months just to switch the strain of influenza virus to be coveredtoo late for the second wave that hit the U.S. in the fall of that year [95] . But the technology for developing nucleic acid-based vaccines could be more readily standardized, and thus take advantage of significant economies of scale and scope [96] .

By 1990, investigators working with mice found that naked DNA or RNA, when injected directly into muscle, could result in the expression of the encoded protein [97] . By 1993, in another mouse-based study, naked DNA coding for a protein from one influenza virus had been found to stimulate the immune response to a related but distinct influenza virus [98] . While naked nucleic acids appeared to be too unstable to be used alone, other investigators were able to package a water-based solution containing RNA inside globules lined with fat molecules [99] .

These initial advances in the use of nucleic acid vaccines offered a scientific basis for moving forward with further research. What's more, preliminary evidence suggested that nucleic acid vaccines for HIV more closely mimicked the form of infection that would adequately stimulate both immune systems [59, [100] [101] [102] . Still, a critical stimulus to the search for a nuclei acid vaccine was the repeated difficulties in getting the live virus vector model to work for HIV.

Researchers began work on a vaccine made from plasmid DNA, a naked, circular loop of double-stranded DNA that naturally exists in bacterial cells. Their efforts culminated in HVTN 505, a phase 2b trial that tested a combination of two components (Fig. 5) : a primer dose of a plasmid DNA-based vaccine expressing six HIV genes, followed by a booster dose of an Ad5 vector containing the same genes [15] . Unfortunately, after two years of follow up, the intervention and placebo groups had indistinguishable rates of HIV infection [15] . (3) The DNA code for the spike is incorporated into plasmid DNA, a naked, circular loop of double-stranded DNA that exits naturally in bacterial cells. In the failed HVTN 505 clinical trial, a plasmid DNA vaccine expressing six genes of HIV was followed by a booster dose an Ad5based viral vector containing the same genes [15] . As of February 15, 2022, sixteen vaccine candidates against COVID-19 using DNA technology were in clinical trials ( Table 2) . Of these, one DNA-based vaccine developed by Zydus Cadila , delivered by skin patch rather than injection, has applied to the Indian government for emergency use authorization [103, 104] .

Once again, failure led to further research to explain the failure. One explanation was that the prime-boost DNA-Ad5 combination used in HVTN 505 likewise stimulated weak antibodies against the Ad5 vector rather than against HIV [105] . To address this possibility, a DNA-AIDSVAX prime-boost combination vaccine is now under evaluation [106] . Another possibility was that a DNA-based vaccine was unlikely to work because the plasmid DNA had too hard a time passing into the target cell nucleus [96] . This stimulated further in interest in mRNA-based vaccines, which only had to get into the host cell cytoplasm to do their job.

But mRNA-based vaccines faced a critical obstacle: mRNA itself stimulated an immune response. That problem was solved in 2005 by chemically tinkering with the natural bases that make up RNA's molecular backbone [107, 108] . A further advance was the development selfamplifying mRNA (or SAM) (Fig.6) . In one study, researchers created an SAM, splicing the mRNA encoding HIV's envelope protein into the mRNA from the alphavirus, then wrapped the hybrid mRNA in a lipid particle [109] . (1) The RNA is extracted from the offending virus and the code for the spike protein is isolated. (2) The section of RNA coding for the spike protein is spliced onto RNA amplifier code from another virus, thus creating self-amplifying mRNA (SAM) [110, 111] .

(3) The SAM, with the natural bases in its backbone modified to reduce its inflammatory potential, is encased in a lipid nanoparticle to enhance its stability. (4) The SAM nanoparticles are injected into the vaccine recipient. mRNA vaccines currently in use include those manufactured by Pfizer-BioNTech [112] and Moderna [113] .

As we've already learned, scientists understood that boosting cellular immune defenses was essential to keeping an HIV-infected person healthy without having to take lifelong antiretroviral medication. To that end, vaccine developers pushed ahead with human trials of mRNA protypes not just for prevention, but also for HIV treatment. In one phase 1 trial, HLPT-S-21-00479_R1 16 investigators injected an mRNA vaccine encoding 16 key fragments of HIV RNA into the lymph nodes of human volunteers who were already chronically infected with HIV. At the highest dose, the vaccine appeared to stimulate the cellular immune response [114] .

By 2019, just months before SARS-Cov-2 was about to enter the world stage, mRNA had reached the forefront of vaccine research, with experimental tests of vaccines against influenza, Zika, and Ebola virus as well [96] . With many of the problems of packaging mRNA out of the way, and with the possibility of streamlined fabrication of mRNA vaccines on demand, it has become clear in retrospect that if mRNA vaccines really worked, they would be the first out of the starting gate in the race for a SARS-CoV-2 vaccine.

By the time of the SARS-CoV-2 outbreak in Wuhan, China, in December 2019, researchers already knew that other human coronaviruses such as SARS and MERS had their own envelope spike glycoprotein that facilitated invasion into human lung cells [115, 116] . With the publication of the complete genetic code of SARS-CoV-2 a month later [117] [118] [119] [120] [121] , researchers quickly confirmed that the spike glycoprotein of this novel coronavirus would play a similar role [122, 123] . Just as the gp120 envelope glycoprotein had become a critical target in the search for an HIV vaccine that began more than three decades earlier, researchers understood that the spike glycoprotein could serve as the critical target for vaccines against SARS-CoV-2. Table 2 shows the specifics. The largest categorynearly one-third of vaccine candidates undergoing clinical testingis based on the purified viral protein model (Fig. 3) . Just as the AIDSVAX vaccines were made from purified gp120 of HIV, so these vaccines are made from the purified spike protein of SARS-CoV-2. Two of these candidates, developed by Novavax [64, 65] and by Sanofi and GSK [66] , have demonstrated efficacy in phase 3 clinical trials and are being submitted for regulatory review.

The STEP trial relied on the Ad5 virus. When that trial failed, the RV144 and Uhambo trials switched to a canarypox viral vector. And when those trials failed, the Mosaico and Imbokodo trials switched to the Ad26 virus. To date, 16 percent of the vaccines against SARS-CoV-2 in Table 2 are based upon the viral vector model (Fig. 4) . Among these vaccines are: the vaccine developed by Janssen and Beth Israel Deaconess Medical Center, which is based upon the Ad26 vector [77, 78] ; the vaccine developed by AstraZeneca and Oxford University, based upon the Ad5 vector [79] ; and the Sputnik V vaccine developed by Gamalaya Research Institute, based upon a priming dose with an Ad26 vector and a booster dose with an Ad5 vector [29, 80] .

[ As further shown in Table 2 , 28 percent of SARS-CoV-2 vaccine candidates in clinical trials are based upon the RNA or DNA nucleic acid platforms (Figs. 5 and 6 ). These include not only the mRNA-based vaccines from Pfizer-BioNTech [112] and Moderna [132, 133] , already approved in the United States and other jurisdictions, but also plasmid DNA-based and other mRNA-based vaccines in development.

One counterargument to our hypothesis is that our experiences with other deadly coronavirusesthe SARS outbreak in 2002-2003 and the continuing reintroduction of MERS on the Arabian Peninsula a decade later [134] are what really prepared us scientifically for the arrival of SARS-CoV-2. Vaccines against SARS and MERS, based upon the technologies described in Table 2 , were already in development, and a few candidates had entered clinical trials [135, 136] .

Quite apart from SARS and MERS, the counterargument continues, our experience with other non-corona viruses contributed to our scientific know-how. The Ebola vaccine, to take one example, is based upon a viral vector derived from the vesicular stomatitis virus (VSV). A critical step in vaccine development was the creation of a genetically engineered VSV that expressed the Zaire Ebola virus (ZEBOV) glycoprotein [137] [138] [139] . The resultant vaccine (rVSV-ZEBOV) was approved in Dec. 2019 [140] . Subsequently, the European Medicines Agency HLPT-S-21-00479_R1 24-Feb-2022 18 approved a separate viral vector vaccine for the Zaire strain of Ebola (commercially called Zabdeno) based upon a combination of two vectors, Ad26 and Modified Vaccinia Ankara [141] .

A mere reference to the development of other vaccines, however, is hardly enough to rebut our principal hypothesis. One would have to contend that these vaccines were developed along tracks independent from and unaided by the search for an HIV vaccine. That would not fit the facts. To the contrary, the successful Ebola vaccines and the unsuccessful HIV vaccines drew from a common knowledge base. The first experimental Ebola virus vaccine to protect nonhuman primates involved an adenovirus 5 vector [142] , the same vector that served as the prototype for the Merck STEP vaccine. It would be a stretch to contend that we have an ample menu of candidate vector virus vaccines against SARS-CoV-2 today because we managed to develop rVSV-ZEBOV for Ebola just in time.

Within the first 15 months of the COVID-19 epidemic, public sector funding of R&D for COVID-19 vaccines already reached $18 to $23 billion [143] , and that did not count at least $70 billion in advanced purchasing agreements [144] . Private sector funding of R&D for COVID -19 vaccines has been more difficult to gauge, as most firms report only total R&D spending without project-specific breakdowns [145, 146] and some of their reported R&D spending was publicly funded [147] . For the full year 2020 and the first quarter of 2021 combined, total R&D spending by Moderna, the developer of one of the currently marketed mRNA vaccines, amounted to $1.7 billion [145, 146] .

By contrast, cumulative undiscounted R&D spending on HIV vaccines from 2000 to 2019 (the last year for which data are available) amounted to US$ 15.3 billion, about 80 percent of which came from the public sector, about 11 percent from philanthropic sources, and the remaining 9 percent from private, commercial firms [148, 149] . This relatively modest investment spread over two decades on an apparently unsuccessful enterprise laid the foundation for a subsequently successful enterprise that saved an estimated 1.1 lives through November 2021 in the U.S. alone [150] .

This massive R&D spillover took place in an economic environment where innovations in vaccine development have been tightly guarded by intellectual property protections. Consider some of the private entities investing in HIV vaccine development that appeared, at least facially, to have sustained losses: VaxGen, the relatively small U.S. biotechnology company that originally owned the rights to the AIDSVAX vaccine; the South Korean investors who entered into a US$ 122 million joint venture with VaxGen to manufacture more than 200 million doses of AIDSVAX vaccines annually; Merck, the pharmaceutical firm that made a multimillion-dollar investment in the STEP Ad5 viral vector vaccine; Sanofi Pasteur, the pharmaceutical firm whose

proprietary canarypox vector ALVAC was tested in the RV144 trial; GlaxoSmithKline (GSK), whose purified gp120 adapted to HIV subtype C was used in the Uhambo trial; and Janssen, whose proprietary AdVac adenovirus 26 vector was tested in the Imbokodo trial.

The failures of these private entities to capitalize on their intellectual property rights were ultimately translated into substantial gains in immunology, virology, molecular biology, and vaccine design generally. The question remains: How exactly did other competitors benefit from these failures?

There is certainly no paucity of economic research examining how one firm learns from other firms' successful innovations [151] [152] [153] . Nor is there any denying that organizations learn from their own failures [154] . During the launch of the Atlantis orbiter in October 2002, a piece of foam insulation broke off, damaging a ring holding a rocket booster but not interfering with the mission. During the launch of Columbia in January 2003, a piece of foam insulation similarly broke off, damaging the left wing, and ultimately resulting in the disastrous disintegration of the orbiter upon reentry and the demise of seven crew members. The response of the National Aeronautics and Space Administration to the Columbia failure, it has been noted, stood in stark contrast to its response to the Atlantis accident, which was perceived as a success [155] .

Here, however, our focus is on the responses of firms and other organizations to the failures of others, particularly in the pharmaceutical and biotechnology sectors. The available evidence supports the proposition that publicly disclosed, phase 2 and 3 clinical trials have been the critical catalysts for knowledge leaks surrounding negative results [156] [157] [158] . In the present HLPT-S-21-00479_R1 24-Feb-2022 20 context, the failed trials enumerated in Table 1 served as key pathways for the diffusion of knowhow that prepared us for SARS-CoV-2 vaccines.

Anecdotal evidence from the therapeutic class of lipid-altering agents brings home the point. In December 2006, Pfizer abruptly halted its phase 3 trial of torcetrapib, a next-generation drug intended to increase blood concentrations of HDL (the "good") cholesterol, on which the firm had already invested US$ 800 million, when interim data showed the intervention group had 82 deaths while the control group had only 51 [159] . The failure appears to have motivated competitor Merck to design a scaled-back trial in patients at highest cardiovascular risk to assess whether its own candidate drug anacetrapib posed the same risks as Pfizer's torcetrapib [160] and, in fact, Merck's larger phase 3 trial of anacetrapib was delayed by about 4 years [161] .

Competitor Roche, by contrast, apparently motivated in part by molecular differences between its own candidate dalcetrapib and Pfizer's torcetrapib, went forward with its phase 3 trial [161, 162] .

Our emphasis on the critical catalytic function of clinical trials should not detract from supporting roles of the public and nonprofit sectors. These sectors have made far and away the largest contribution to HIV vaccine R&D over the last two decades [148, 149] . The Uhambo, Imbokodo and Mosaic trials were conducted as collaborations between public, private nonprofit and commercial partners. While VaxGen, the developer of the AIDSVAX version of purified gp120, exited the market, the firm negotiated its intellectual property rights to a nonprofit foundation in 2008. AIDSVAX and related glycoproteins were subsequently employed as boosters in the RV144, Uhamabo, Mosaico and Imbokodo trials.

That said, we still need to acknowledge that a substantial majority of vaccines currently in useand of vaccine candidates that have failedhave been developed by private firms taking advantage of their patents and trade secrets. These private firms ultimately had to learn from each other's failures. including the United States [163, 164] . Delta was approximately 60 percent more transmissible than the Alpha variant (B.1.1.7) that had previously dominated the United Kingdom, or about 2.4 times more transmissible than the ancestral strain [165] . The Omicron variant (B.1.1.529) , which has swept through the world since its first appearance in late November 2021, appears to be about twice as transmissible as Delta [166] , though mutations in its spike glycoprotein have made it more prone to attack the upper airways of the human respiratory system rather than the deep lung [167] .

Each new variant-driven wave seems to blindside medical gurus and public policymakers, who are forced to hastily retract their rosy forecasts that the denouement was finally upon us. Yet in a real sense, we are observing no more than a scientific replay of the ongoing struggle to find a vaccine against HIV.

While SARS-CoV-2 mutates at a lower rate than HIV, the COVID-19 pandemic has now extended far enough and lasted long enough that mutations producing these new variants have inevitably emerged. Aside from the sheer volume and scope of infections as a mutation driver, there is evidence that immunocompromised individuals who do not rapidly clear their infection may serve as long-term reservoirs for a cascade of viral mutations [168, 169] . In fact, the strikingly distinct genetic signature of 30 bundled mutations in the spike glycoprotein of the Omicron variant quite likely arose from long-term SARS-CoV-2 infection in an individual with untreated HIV [170] .

In a sense, we have come full circle. The recurrent waves of new SARS-CoV-2 variants have been driven not so much by random mutations among distinct infected individuals as by clustered, serial mutations within the same infected individual. And the irony is that the most important way to dampen the waves of SARS-CoV-2 may be to get nearly everyone with HIV on antiviral therapy or, better still, finally come up with a vaccine against HIV [170] .

The extraordinarily high rates of efficacy against symptomatic infection from the ancestral strain of SARS-CoV-2, observed in the phase 3 clinical trials of the two mRNA vaccines candidates [112, 113] , created the illusion that these vaccines might come close to providing sterilizing immunity. Genuine sterilizing immunity against SARS-CoV-2, however, would require a high-level immune response at the virus' point of entry through the nose and mouth [171, 172] , just as sterilizing immunity against HIV would require a comparable response HLPT-S-21-00479_R1 24-Feb-2022 22 at the mucous membranes of the vagina and rectum [173, 174] . When it was first noted that vaccinated individuals were becoming infected with the Delta variant [175, 176] , these cases were misleadingly labeled breakthrough infections.

In fact, we have every reason to think that currently available, effective vaccines against SARS-CoV-2 adhere instead to the infection-permissive model of protection. These vaccines did not prevent infection entirely, but rather shifted the distribution of severity backward to the point where a very substantial proportion of those infected had no symptoms. Strictly speaking, they were all breakthrough infections. With the subsequent advent of Delta and Omicron, the distribution of severity has shifted forward somewhat, so that these vaccines are less effective against symptomatic infection but still offer powerful protection against hospitalization and death [177] . We could have anticipated all this from our string of failures to develop an HIV vaccine but seem to have forgotten much along the way.

Our struggle with HIV vaccines taught us about immune escape. The halving of the efficacy of the RV-144 vaccine from 60 percent at one year to 30 percent after 3 years [14, 92, 93] showed us that immune escape could be as much a consequence of waning immune defenses as it was a result of viral hypermutability. We have now relearned that the degradation of the humoral antibody response to SARS-CoV-2 began soon after the most recent dose of mRNA vaccine [178, 179] , and that the immune escape observed with the recent Delta and Omicron variants was not entirely due to their spike glycoprotein mutations [180, 181] . Yet when data from Israel, where the Pfizer mRNA vaccine had been in widespread use, first signaled a marked waning in vaccine effectiveness [182] to the point where a booster dose was recommended

[183], the news was received as a lightning bolt.

The string of HIV vaccine failures also taught us a lesson about combination vaccines.

Here, we do not refer to the classic combinations against measles, mumps, and rubella, or against diphtheria, tetanus and pertussis, where the components work independently to prevent distinct diseases. Instead, we focus on the combination vaccines where the components are intended to act synergistically to achieve immune protection against the same disease. Early evidence that the Oxford-AstraZeneca viral vector vaccine could be combined with the Pfizer-BioNTech mRNA vaccine was greeted with fanfare [184] . Yet in the RV144, Uhamabo, Imbokodo, and Mosaico trials, a viral vector had already been combined with a purified protein vaccine. In HVTN 505, a nucleic acid-based vaccine had already been combined with a viral vector vaccine [15] .

The economic incentive to develop an HIV vaccine depends on the extent of the market.

By 2020, the incidence of newly acquired HIV infections worldwide had dropped to 1.5 million annually, down 30 percent since 2010 [185] . This figure is dwarfed by the more than 400 million cases of COVID-19 reported worldwide since late 2019 [186] . Still, the number of persons at high risk for contracting HIV is likely to be at least two orders of magnitude higher than the current incidence, that is, around 150 million [187] . The most obvious area of reverse spillover is the application of new mRNA technology to the development of HIV vaccines. The spike protein of SARS-CoV-2 not only serves as the key to unlocking the host cell membrane, but it has also turned out to be an ideal immunogen. While scientists have long known that the gp120 glycoprotein molecule is the corresponding key on HIV, there is still considerable uncertainty as to what HIV-specific molecules are the most immunogenic. The AIDSVAX trials demonstrated early on that pure gp120 by itself was not enough [11, 12] . Thus far, a significant obstacle in HIV vaccine development has been the enormous investment in time and resources required to develop and test the handful of potential immunogens other than gp120 that have gone into the booster shots of the RV144, Uhambo, Mosaico and Imbokodo trial vaccines [8, 14, 17, 18, 188, 189] . In this sense, the learning-bydoing process in HIV vaccine development has become a numbers game. In the face of so many subtypes of HIV, how many different surface glycoproteins and structural proteins can we cram into a single booster?

That's where the economies of scale and scope inherent in mRNA technology may come into play. Investigators have been able to construct model mRNA vaccines that contain a wide HLPT-S-21-00479_R1 24-Feb-2022 24 variety of surface glycoproteins and structural proteins from various subtypes of HIV. Some of these mRNA prototypes have already been tested in animal models [190] . Phase 1 trials of two mRNA-based candidate vaccines against HIV are now in the recruiting phase [191] .

The author has received no direct or indirect remuneration for this article. The author discloses that a family member, M. Scott Harris MD, is chief medical officer of Altimmune, a biopharmaceutical company with two COVID-19 vaccine prototypes previously in development.

The author has no financial or other interests in Altimmune's products, and no one employed by or affiliated with Altimmune had any part in drafting or reviewing this article. Otherwise, the author has no actual or potential conflicts of interest to declare.

The author has no funding sources to declare.

This article does not involve research on human subjects.

All data relied upon in this article are publicly available and cited in the References.

HLPT-S-21-00479_R1 24-Feb-2022 

The search for effective HIV vaccines

Shots in the Dark: The Wayward Search for an AIDS Vaccine

HIV-Host Interactions: Implications for Vaccine Design

Virus-Like-Vaccines against HIV. Vaccines (Basel)

A Likely AIDS Cause, but Still no Cure

Experimental HIV Vaccine Regimen Ineffective in Preventing HIV. 2020

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in lowrisk, HIV-uninfected, South African adults: a phase 1/2 trial

HVTN 702 clinical trial of an HIV vaccine stopped

The Economic Implications of Learning by Doing Review of Economic Studies

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

National Library of Medicine, A Study of Heterologous Vaccine Regimen of

Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cisgender Men and/or Transgender Individuals (MOSAICO)

The Search for R&D Spillovers

Knowledge Spillovers, Innovation and Growth

Lessons from the Salk polio vaccine: methods for and risks of rapid translation

Efficacy of Live, Attenuated Measles-Virus Vaccine Given With Human Immune Globulin

Advances in mRNA Vaccines for Infectious Diseases. Front Immunol

Developments in rabies vaccines

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

Vaccine adjuvants: Why and how

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines

WHO, International Travel and Health: Hepatitis A Vaccine. 2020

Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines

Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program

New HIV Vaccine Proves Successful In Phase 1 Human Trial

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety

Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence

Correlates of protection induced by vaccination

Herpesviruses: latency and reactivation -viral strategies and host response

HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex

Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection

Immunological correlates of protection from HIV infection and disease

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load. Front Immunol

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay

The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration

Emerging vaccine-breakthrough SARS-CoV-2 variants

Centers for Disease Control and Prevenetion, How Flu Viruses Can Change: -Drift‖ and -Shift‖

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

Evolutionary and immunological implications of contemporary HIV-1 variation

The secret life of viral entry glycoproteins: moonlighting in immune evasion

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. iScience

Antibody neutralization and escape by HIV-1

Prospects for an AIDS vaccine

Immunologic basis of vaccine vectors

Why we don't have an HIV vaccine, and how we can develop one. Health Aff (Millwood)

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

National Institutes of Health, U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization

Submits-Request-to-the-U-S-FDA-for-Emergency-Use-Authorization-of-COVID-19-Vaccine

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

HIV-1: nature's master of disguise

SARS-CoV-2 variants, spike mutations and immune escape

Prospects for an AIDS vaccine

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera

Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate

Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo

The T cell immune response against SARS-CoV-2

An effective HIV vaccine: A combination of humoral and cellular immunity?

Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose

Mapping of a 14,000-dalton antigen to early region 4 of the human adenovirus 5 genome

Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cellmediated protective immunity against malaria

Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine

Use of adenovirus in vaccines for HIV

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

Immunizations Are Discontinued in Two HIV Vaccine Trials

Overview of STEP and Phambili trial results: two phase IIb test-ofconcept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men

Lessons learned from HIV vaccine clinical efficacy trials

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. Vaccine

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa

SARS-CoV-2 Vaccines: Status Report. Immunity, 2020

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Direct gene transfer into mouse muscle in vivo

Heterologous protection against influenza by injection of DNA encoding a viral protein

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

Zydus applies to the DCGI for EUA to launch ZyCoV-D, the world's first Plasmid DNA vaccine for COVID-19 (Press Release)

A phase III, randomized, multi-centre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

Potent immune responses in rhesus macaques induced by nonviral delivery of a selfamplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion

mRNA vaccines -a new era in vaccinology

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

Efficient Reverse Genetic Systems for Rapid Genetic Manipulation of Emergent and Preemergent Infectious Coronaviruses

Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice

Author Correction: A new coronavirus associated with human respiratory disease in China

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

World Health Organization, Candidate Vaccine Landscape and Tracker

Virus-like particles as HIV-1 vaccines

Virus-like particles: designing an effective AIDS vaccine

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel)

A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial

Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? Front Immunol

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Costly Lessons From the 2015 Middle East Respiratory Syndrome Coronavirus Outbreak in Korea

Molecular Basis of Coronavirus Virulence and Vaccine Development

Coronavirus vaccine development: from SARS and MERS to COVID-19

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Effective post-exposure treatment of Ebola infection

rVSVDeltaG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

Development of a preventive vaccine for Ebola virus infection in primates

Global Health Centre, Vaccine Purchases and Manufacturing Agreements

COVID-19 significant contributor to biopharma's $44B R&D spend in 2020

COVID-19 R&D drives sector's research spending in Q1

Pfizer Vaccine's Funding Came From Berlin

Resource Tracking for HIV Prevention R&D Working Group (RTWG), HIV Prevention Research & Development Investments 2018: Investing to end the epidemic

Resource Tracking for HIV Prevention R&D Working Group (RTWG), HIV Prevention Research & Development Investments. 2020

The U.S. COVID-19 Vaccination Program at One Year: How Many Deaths and Hospitalizations Were Averted?

Technological Opportunity and Spillovers of R & D: Evidence from Firms' Patents, Profits, and Market Value

Costs of Production, Intra-and Interindustry R&D Spillovers: Canadian Evidence

Spillovers in product and process innovation:Evidence from manufacturing firms

Learning to learn from failures: the impact of operating experience on railroad accident responses. Industrial and Corporate Change

Failing to Learn? The Effects of Failure and Success on Organizational Learning in the Global Orbital Launch Vehicle Industry

Learning from Failures or Failing to Learn? Lessons from Pharmaceutical R&D

Learning from successes and failures in pharmaceuticalR&D

Trials and Terminations: Learning from Competitors' R&D Failures. Management Science

Pfizer stops clinical trials of heart drug

Safety of anacetrapib in patients with or at high risk for coronary heart disease

Learning lessons from Pfizer's $800 million failure

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

Delta variant triggers dangerous new phase in the pandemic

COVID-19 Delta variant detected in 98 countries, continues to evolve and mutate, warns WHO

What We Know About the Dangerous Delta Variant

From Delta to Omicron: analysing the SARS-CoV-2 epidemic in France using variant-specific screening tests

Omicron's feeble attack on the lungs could make it less dangerous

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA. Emerg Infect Dis

Africa: tackle HIV and COVID-19 together

The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine

How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked

How can we design better vaccines to prevent HIV infection in women? Front Microbiol

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections

Early Release): p. ePub

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV

Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2

2 (Delta) Variant -National Healthcare Safety Network

COVID-19 Incidence and Hospitalization During the Delta Surge Were Inversely Related to Vaccination Coverage Among the Most Populous U.S. Counties

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort

Mix-and-match COVID vaccines trigger potent immune response

World Health Organization, WHO Coronavirus (COVID-19) Dashboard

Who Is at Risk for HIV?

An Optimal Isolation Policy for an Epidemic

Another HIV vaccine strategy fails in large-scale study

An Env-Gag mRNA vaccine protects macaques from heterologous tier-2 SHIV infection

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine